2 250

Cited 6 times in

The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea

DC FieldValueLanguage
dc.contributor.author김진석-
dc.contributor.author민유홍-
dc.contributor.author정준원-
dc.date.accessioned2015-01-06T16:23:37Z-
dc.date.available2015-01-06T16:23:37Z-
dc.date.issued2014-
dc.identifier.issn0939-5555-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/98021-
dc.description.abstractTo identify the role of therapeutic drug monitoring of itraconazole (ITZ) in the setting of empirical antifungal therapy with intravenous (IV) ITZ, we performed a multicenter, prospective study in patients with hematological malignancies who had received antifungal prophylaxis with ITZ oral solution (OS). We evaluated the plasma levels of ITZ and hydroxy (OH) ITZ both before initiation of IV ITZ and on days 5–7 of IV ITZ. A total of 181 patients showed an overall success rate of 68.0 %. Prolonged baseline neutropenia and accompanying cardiovascular comorbidity were significantly associated with poor outcomes of the empirical antifungal therapy (P = 0.005 and P = 0.001, respectively). A significantly higher trough plasma level of OH ITZ per body weight was found in the patients who achieved success with empirical antifungal therapy (P = 0.036). There were no significant correlations between plasma concentrations of ITZ/OH ITZ (baseline or trough levels) and toxicities. Seven patients had a discontinuation of ITZ therapy due to toxicity. This study demonstrated that IV ITZ as empirical antifungal therapy was effective and therapeutic drug monitoring was helpful to estimate the outcome of empirical antifungal therapy in patients receiving antifungal prophylaxis with ITZ OS. To predict the outcome of empirical antifungal therapy with IV ITZ, we should evaluate baseline clinical characteristics and also perform the therapeutic drug monitoring of both ITZ and OH ITZ.-
dc.description.statementOfResponsibilityopen-
dc.format.extent33~42-
dc.relation.isPartOfANNALS OF HEMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdministration, Oral-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntifungal Agents/administration & dosage-
dc.subject.MESHAntifungal Agents/adverse effects-
dc.subject.MESHAntifungal Agents/blood-
dc.subject.MESHAntifungal Agents/therapeutic use*-
dc.subject.MESHChemotherapy-Induced Febrile Neutropenia/complications-
dc.subject.MESHDrug Monitoring-
dc.subject.MESHFemale-
dc.subject.MESHHematologic Neoplasms/complications-
dc.subject.MESHHumans-
dc.subject.MESHItraconazole/administration & dosage-
dc.subject.MESHItraconazole/adverse effects-
dc.subject.MESHItraconazole/analogs & derivatives-
dc.subject.MESHItraconazole/blood-
dc.subject.MESHItraconazole/therapeutic use*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMycoses/drug therapy*-
dc.subject.MESHMycoses/etiology-
dc.subject.MESHMycoses/prevention & control-
dc.subject.MESHProspective Studies-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titleThe relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorJin Seok Kim-
dc.contributor.googleauthorJune-Won Cheong-
dc.contributor.googleauthorYeo-Kyeoung Kim-
dc.contributor.googleauthorJinny Park-
dc.contributor.googleauthorYeung-Chul Mun-
dc.contributor.googleauthorHye Jin Kang-
dc.contributor.googleauthorHyeon Gyu Yi-
dc.contributor.googleauthorJe-Hwan Lee-
dc.contributor.googleauthorYang Soo Kim-
dc.contributor.googleauthorHun-Mo Ryoo-
dc.contributor.googleauthorSung-Hyun Kim-
dc.contributor.googleauthorHo Young Kim-
dc.contributor.googleauthorJin Young Kim-
dc.contributor.googleauthorDong-Gun Lee-
dc.contributor.googleauthorHoon-Gu Kim-
dc.contributor.googleauthorHawk Kim-
dc.contributor.googleauthorYoung-Don Joo-
dc.contributor.googleauthorYoo Hong Min-
dc.identifier.doi10.1007/s00277-013-1826-x-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01017-
dc.contributor.localIdA01407-
dc.contributor.localIdA03729-
dc.relation.journalcodeJ00161-
dc.identifier.eissn1432-0584-
dc.identifier.pmid23807252-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00277-013-1826-x-
dc.subject.keywordHematological malignancy-
dc.subject.keyworditraconazole-
dc.subject.keywordHydroxy itraconazole-
dc.subject.keywordEmpirical antifungal therapy-
dc.subject.keywordTherapeutic drug monitoring-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.alternativeNameMin, Yoo Hong-
dc.contributor.alternativeNameCheong, June Won-
dc.contributor.affiliatedAuthorKim, Jin Seok-
dc.contributor.affiliatedAuthorMin, Yoo Hong-
dc.contributor.affiliatedAuthorCheong, June-Won-
dc.rights.accessRightsfree-
dc.citation.volume93-
dc.citation.number1-
dc.citation.startPage33-
dc.citation.endPage42-
dc.identifier.bibliographicCitationANNALS OF HEMATOLOGY, Vol.93(1) : 33-42, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.